Six1 induces protein synthesis signaling expression in duck myoblasts mainly via up-regulation of mTOR

Genetics and Molecular Biology

Volumn 39, Issue 1, 2016, Pages 151-161

  Wang, Haohan ^a   Li, Xinxin ^a   Liu, Hehe ^a   Sun, Lingli ^a   Zhang, Rongping ^a   Li, Liang ^a   Wangding, Mincheng ^a   Wang, Jiwen ^a  

^a SICHUAN AGRICULTURAL UNIVERSITY   (China)

Author keywords

Duck; MTOR; PEGFP duSix1; Protein metabolism signaling; Six1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ATROGIN 1; ENHANCED GREEN FLUORESCENT PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MUSCLE PROTEIN; MUSCLE RING FINGER 1 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR SIX1;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DUCK; EMBRYO; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; MYOBLAST; NONHUMAN; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84961678198     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/1678-4685-GMB-2015-0075     Document Type: Article

References (41)

1. Aguilar V, Alliouachene S, Sotiropoulos A, Sobering A, Athea Y, Djouadi F, Miraux S, Thiaudiere E, Foretz M, Viollet B, et al. (2007) S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab 5:476-487.
2. Bernardo BC, Weeks KL, Pretorius L and McMullen JR (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol Ther 128:191-227.
3. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ and Yancopoulos GD (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell. Biol 3:1014-1019.
4. Brodbeck S and Englert C (2004) Genetic determination of nephrogenesis: The Pax/Eya/Six gene network. Pediatr Nephrol 19:249-255.
5. Brugmann SA, Pandur PD, Kenyon KL, Pignoni F and Moody SA (2004) Six1 promotes a placodal fate within the lateral neurogenic ectoderm by functioning as both a transcriptional activator and repressor. Development 131:5871-5881.
6. Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP, Gutkind JS and Li W (2002) PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 21:5289-5300.
7. Dorn 2nd GW(2007) The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49:962-970.
8. Dorn 2nd GW and Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527-537.
9. Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, Steenbergh pH and Sussenbach JS (1997) Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 272:31163-31171.
10. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A and Chen J (2001) Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294:1942-1945.
11. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R and Ford HL (2012) Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 31:552-562.
12. Ford HL, Landesman-Bollag E, Dacwag CS, Stukenberg PT, Pardee AB and Seldin DC (2000) Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J Biol Chem 275:22245-22254.
13. Foster DA (2007) Regulation of mTOR by phosphatidic acid? Cancer Res 67:1-4.
14. Fougerousse F, Durand M, Lopez S, Suel L, Demignon J, Thornton C, Ozaki H, Kawakami K, Barbet P, Beckmann JS and Maire P (2002) Six and Eya expression during human somitogenesis and MyoD gene family activation. J Muscle Res Cell Motil 23:255-264.
15. Gao T, Furnari F and Newton AC (2005) PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18:13-24.
16. Giordani J, Bajard L, Demignon J, Daubas P, BuckinghamMand Maire P (2007) Six proteins regulate the activation of Myf5 expression in embryonic mouse limbs. Proc Natl Acad Sci U S A 104:11310-11315.
17. Glass DJ (2005) Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37:1974-1984.
18. Grifone R, Demignon J, Houbron C, Souil E, Niro C, Seller MJ, Hamard G and Maire P (2005) Six1 and Six4 homeoproteins are required for Pax3 and Mrf expression during myogenesis in the mouse embryo. Development 132:2235-2249.
19. Grifone R, Laclef C, Spitz F, Lopez S, Demignon J, Guidotti JE, Kawakami K, Xu PX, Kelly R, Petrof BJ, et al. (2004) Six1 and Eya1 expression can reprogram adult muscle from the slow-twitch phenotype into the fast-twitch phenotype. Mol Cell Biol 24:6253-6267.
20. Kanda S, Hodgkin MN, Woodfield RJ, Wakelam MJ, Thomas G and Claesson-Welsh L (1997) Phosphatidylinositol 3’-kinase-independent p70 S6 kinase activation by fibroblast growth factor receptor-1 is important for proliferation but not differentiation of endothelial cells. J Biol Chem 272:23347-23353.
21. Kimball SR (2007) The role of nutrition in stimulating muscle protein accretion at the molecular level. Biochem Soc Trans 35:1298-1301.
22. Kostek MC, Chen YW, Cuthbertson DJ, Shi R, Fedele MJ, Esser KA and Rennie MJ (2007) Gene expression responses over 24 h to lengthening and shortening contractions in human muscle: Major changes in CSRP3, MUSTN1, SIX1, and FBXO32. Physiol Genomics 31:42-52.
23. Laclef C, Hamard G, Demignon J, Souil E, Houbron C and Maire P (2003) Altered myogenesis in Six1-deficient mice. Development 130:2239-2252.
24. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE and Goldberg AL (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18:39-51.
25. Lee SH, Kim J, Ryu JY, Lee S, Yang DK, Jeong D, Kim J, Lee SH, Kim JM, Hajjar RJ and Park WJ (2012) Transcription coactivator Eya2 is a critical regulator of physiological hypertrophy. J Mol Cell Cardiol 52:718-726.
26. Leger B, Cartoni R, Praz M, Lamon S, Deriaz O, Crettenand A, Gobelet C, Rohmer P, Konzelmann M, Luthi F and Russell AP (2006) Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. J Physiol 576:923-933.
27. Liu P, Xu B, Li J and Lu H (2008) LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway. Biochem Biophys Res Commun 377:187-190.
28. Louis E, Raue U, Yang Y, Jemiolo B and Trappe S (2007) Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle. J Appl Physiol 103:1744-1751.
29. Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, ThelenMand Hemmings BA (2001) Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 294:374-380.
30. McCarthy JJ, Mula J, Miyazaki M, Erfani R, Garrison K, Farooqui AB, Srikuea R, Lawson BA, Grimes B, Keller C, et al. (2011) Effective fiber hypertrophy in satellite cell-depleted skeletal muscle. Development 138:3657-3666.
31. McLoughlin TJ, Smith SM, DeLong AD, Wang H, Unterman TG and Esser KA (2009) FoxO1 induces apoptosis in skeletal myotubes in a DNA-binding-dependent manner. Am J Physiol Cell Physiol 297:C548-555.
32. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL and Rosenthal N (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27:195-200.
33. Pellegatta F, Chierchia SL and Zocchi MR (1998) Functional association of platelet endothelial cell adhesion molecule-1 and phosphoinositide 3-kinase in human neutrophils. J Biol Chem 273:27768-27771.
34. Sakurai Y, Aarsland A, Herndon DN, Chinkes DL, Pierre E, Nguyen TT, Patterson BW and Wolfe RR (1995) Stimulation of muscle protein synthesis by long-term insulin infusion in severely burned patients. Ann Surg 222:283-294; 294-297.
35. Sandri M (2008) Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 23:160-170.
36. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL and Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159-168.
37. Tipton KD, Elliott TA, Ferrando AA, Aarsland AA and Wolfe RR (2009) Stimulation of muscle anabolism by resistance exercise and ingestion of leucine plus protein. Appl Physiol Nutr Metab 34:151-161.
38. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J and Thomas G (2004) Absence of S6K1 protects against ageand diet-induced obesity while enhancing insulin sensitivity. Nature 431:200-205.
39. Wang H, Jint H, Liu H, Sun L, Li X, Yang C, Zhang R, Li L and Wang J (2014) Molecular cloning and expression pattern of duck Six1 and its preliminary functional analysis in myoblasts transfected with eukaryotic expression vector. Indian J Biochem Biophys 51:271-281.
40. Yajima H, Motohashi N, Ono Y, Sato S, Ikeda K, Masuda S, Yada E, Kanesaki H, Miyagoe-Suzuki Y, Takeda S and Kawakami K (2010) Six family genes control the proliferation and differentiation of muscle satellite cells. Exp Cell Res 316:2932-2944.
41. Yu Y, Davicioni E, Triche TJ and Merlino G (2006) The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res. 66:1982-1989.